Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Enveric Biosciences, Inc. (AMRH)
|
Add to portfolio |
|
|
|
| Price: |
$1.04
| | Metrics |
| OS: |
2.15
|
M
| |
-464
|
% ROE
|
| Market cap: |
$2.23
|
M
| |
|
|
|
Net cash:
|
$7.08
|
M
| |
$3.30
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($20.7)
|
M
| |
|
|
|
EBIT
|
($21.1)
|
M
| |
|
|
| EPS |
($12.89)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.0 | 0.0 | 0.0 | 39.9 | 43.0 | 48.6 | 19.2 | 14.5 |
| Revenue growth | | | -100.0% | -7.2% | -11.5% | 152.6% | 32.4% | 22047.0% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 31.8 | 34.0 | 38.4 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 8.2 | 9.0 | 10.2 | 19.2 | 14.5 |
| Gross margin | | | | 20.4% | 20.9% | 21.1% | 100.0% | 100.0% |
| Selling, general and administrative | | | | 12.2 | 10.8 | 18.5 | 12.3 | |
| Sales and marketing | | | | | | | | 0.1 |
| Research and development | 8.0 | 4.8 | 0.2 | | | | | |
| General and administrative | 11.6 | 20.5 | 5.4 | | | | | |
| EBITA | -19.8 | -25.3 | -5.6 | -4.0 | 5.1 | -7.2 | -5.1 | -0.9 |
| EBITA margin | | | | -10.1% | 11.9% | -14.8% | -26.7% | -6.4% |
| Amortization of intangibles | 0.2 | 0.6 | | 2.3 | 2.9 | 3.2 | 1.4 | 0.2 |
| EBIT | -20.0 | -25.9 | -5.6 | -6.3 | 2.2 | -10.4 | -6.5 | -1.1 |
| EBIT margin | | | | -15.8% | 5.2% | -21.4% | -34.0% | -7.5% |
| Pre-tax income | -20.0 | -56.4 | -7.0 | -5.2 | -10.5 | -11.5 | -6.5 | -0.9 |
| Income taxes | -1.5 | -7.5 | 0.0 | 0.4 | 6.3 | -2.4 | -3.7 | -0.1 |
| Tax rate | 7.4% | 13.2% | 0.0% | | | 20.9% | 57.4% | 13.6% |
| Net income | -18.8 | -49.0 | -7.0 | -6.0 | -19.5 | -11.2 | -2.8 | -0.8 |
| Net margin | | | | -15.1% | -45.3% | -23.0% | -14.5% | -5.6% |
| |
| Diluted EPS | ($13.00) | ($103.69) | ($1.22) | ($2.83) | ($20.47) | ($0.75) | ($0.21) | ($0.07) |
| Shares outstanding (diluted) | 1.4 | 0.5 | 5.8 | 2.1 | 1.0 | 15.0 | 13.1 | 11.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|